Sign up
Log in
TrueBlue Board Unanimously Rejects HireQuest's $7.50/Shr All-Stock Acquisition Proposal
Share
Listen to the news

Proposal Significantly Undervalues the Company and Is Not in the Best Interest of Shareholders

Shareholders Do Not Need to Take Action at This Time

TrueBlue (NYSE:TBI), a leading provider of specialized workforce solutions, today announced that its Board of Directors (the "Board") unanimously rejected an unsolicited, non-binding proposal from HireQuest, Inc., regarding a potential all-stock proposal to acquire all common shares of TrueBlue at $7.50 per share.

Following careful evaluation and consistent with its fiduciary duties, the Board declined HireQuest's proposal. Prior to this latest offer, in February 2025, the Board previously considered, and rejected, an unsolicited, non-binding proposal from HireQuest at a price of up to $12.30 per share of TrueBlue. HireQuest's latest proposal to acquire TrueBlue at $7.50 per share, which was received on May 9, 2025, represents an opportunistic attempt to acquire the Company and significantly undervalues the business and its potential.

The Board is committed to maximizing value for all shareholders and believes that the proposed transaction does not meet these objectives. The Board continues to believe that the proposed transaction is not in the best interests of the Company's shareholders. TrueBlue remains focused on executing its strategic plan and creating long-term value for its shareholders.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.